Cart summary

You have no items in your shopping cart.

Edaravone

SKU: orb1223731

Description

Edaravone(MCI-186), a strong novel free radical scavenger, is used for treatment of patients with acute brain infarction. (In Vitro):Edaravone performs both preventative and therapeutic effects against toxicity of glutamate. Pretreatment of edaravone reduces the toxicity of glutamate towards SGNs. Edaravone reduces apoptosis and necrosis caused by glutamate. Pretreatment of edaravone (500 μM) reverses these changes to approximately normal levels. The protective effect of edaravone on SGNs against glutamate-induced apoptosis is associated with PI3K/Akt pathway and Bcl-2 protein family.(In Vivo):Edaravone exerts neuroprotective effects by inhibiting endothelial injury and by ameliorating neuronal damage in brain ischemia. Edaravone provides the desirable features of NOS: it increases eNOS (beneficial NOS for rescuing ischemic stroke) and decreases nNOS and iNOS (detrimental NOS). Post-reperfusion brain edema and hemorrhagic events induced by thrombolytic therapy may be reduced by edaravone pretreatment. Edaravone significantly decreases infarct volume, with the average infarct volume in the edaravone-treated rats (227.6 mm3) being significantly lower than that in the control rats (264.0 mm3). Edaravone treatment also decreases the postischemic hemorrhage volumes (53.4 mm3 in edaravone-treated rats vs 176.4 mm3 in controls). In addition, the ratio of hemorrhage volume to infarct volume is lower in the edaravone-treated rats (23.5%) than in the untreated rats (63.2%). In edaravone (20 mg/kg)-treated rats, astrocyte activity (glial fibrillary acidic protein) and apoptotic cells (caspase-3) are decreased on the corpus callosum, germinal matrix, and cerebral cortex.

Images & Validation

Key Properties

CAS Number89-25-8
MW174.2
Purity>98% (HPLC)
FormulaC10H10N2O
SMILESO=C1CC(C)=NN1C2=CC=CC=C2
TargetFree radical scavengers
SolubilityEthanol: 35 mg/mL (200.91 mM); DMSO: 35 mg/mL (200.91 mM)

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

Edaravone | NSC 2629

Similar Products

  • Edaravone [orb1310644]

    >99.99% (May vary between batches)

    89-25-8

    174.20

    C10H10N2O

    1 ml x 10 mM (in DMSO), 5 g
  • Edaravone-d5 [orb1992870]

    1228765-67-0

    179.23

    C10H10N2O

    5 mg, 1 mg
  • Edaravone dimer impurity [orb3136871]

    177415-76-8

    346.38

    C20H18N4O2

    10 mg, 50 mg
  • Edaravone (Standard) [orb3139607]

    89-25-8

    174.20

    C10H10N2O

    25 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Edaravone (orb1223731)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%